Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352027 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00352027 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 81 participants.
The verdict
NCT00352027, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.
Interventions
- DRUG Cyclophosphamide
- DRUG Vincristine
- DRUG Vinblastine
- DRUG Adriamycin®
- DRUG Nitrogen Mustard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2006-07-20 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352027
The ClinicalTrials.gov registry entry for NCT00352027 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00352027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352027 about?
NCT00352027 is a clinical study titled "Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma". The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hy...
What is the current status of trial NCT00352027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2006-07-20. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT00352027?
The interventions under investigation include: Cyclophosphamide (DRUG), Vincristine (DRUG), Vinblastine (DRUG), Adriamycin® (DRUG), Nitrogen Mustard (DRUG).
Who is sponsoring clinical trial NCT00352027?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.